Unlock stock picks and a broker-level newsfeed that powers Wall Street.

ASX Growth Stocks With High Insider Ownership To Watch

In This Article:

As the Australian market opens nearly flat amid the kickoff of the 2025 election campaign, investors are closely monitoring potential economic impacts and policy shifts that may arise in the coming weeks. In such a climate, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those closest to the business and may offer resilience during uncertain times.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Alfabs Australia (ASX:AAL)

10.8%

40.9%

Cyclopharm (ASX:CYC)

11.3%

97.8%

Fenix Resources (ASX:FEX)

21.1%

45.1%

Acrux (ASX:ACR)

15.6%

106.9%

Newfield Resources (ASX:NWF)

31.5%

72.1%

AVA Risk Group (ASX:AVA)

16%

108.2%

Titomic (ASX:TTT)

11.2%

77.2%

Plenti Group (ASX:PLT)

12.7%

120.1%

BlueBet Holdings (ASX:BBT)

39.2%

77.5%

Findi (ASX:FND)

35.6%

120.7%

Click here to see the full list of 95 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Here we highlight a subset of our preferred stocks from the screener.

Clinuvel Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and internationally with a market cap of A$583.38 million.

Operations: The company's revenue is primarily derived from the Biopharmaceutical Sector, amounting to A$91.02 million.

Insider Ownership: 10.4%

Earnings Growth Forecast: 25.8% p.a.

Clinuvel Pharmaceuticals shows strong growth potential with forecasted annual earnings growth of 25.8%, outpacing the Australian market. Recent revenue growth to A$43.29 million and a strategic focus on clinical development and product expansion, including the upcoming CYACELLE Radiant launch, support this trajectory. Despite CEO Dr. Philippe Wolgen's temporary leave, leadership remains stable with Lachlan Hay as Acting CEO. The recent share buyback program indicates confidence in future prospects despite low insider trading activity recently reported.

ASX:CUV Earnings and Revenue Growth as at Mar 2025
ASX:CUV Earnings and Revenue Growth as at Mar 2025

Develop Global

Simply Wall St Growth Rating: ★★★★★★

Overview: Develop Global Limited, with a market cap of A$774.14 million, is involved in the exploration and development of mineral resource properties in Australia.